New tests launched in March


New Tests

In March 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The new tests that launched in March 2022 by Mayo Clinic Laboratories:

RLTE4 | Leukotriene E4, Random, Urine

This test is intended for an aid to evaluate patients suspected of having systemic mastocytosis using random urine collections.

TLTE4 | Leukotriene E4, 24 Hour, Urine

This test is intended for an aid to evaluate patients suspected of having systemic mastocytosis using 24-hour urine collections.

AFXN | Friedreich Ataxia, Repeat Expansion Analysis, Varies

This test is intended for molecular confirmation of clinically suspected Friedreich ataxia.

FHV8P | Herpesvirus 8 (HHV-8) DNA, Quantitative Real-Time PCR

This test is intended for real-Time Polymerase Chain Reaction, RT-PCR.

FJCQP | JC Polyoma Virus DNA, Quantitative Real-Time PCR, Plasma

This test is intended for real-Time Polymerase Chain Reaction (RT-PCR).

FHV6P | Herpesvirus 6 (HHV-6) DNA, Quantitative Real-Time PCR

This test is intended for real Time PCR.

FADNA | Adenovirus DNA, Quantitative Real-Time PCR

This test is intended for real-Time Polymerase Chain Reaction (RT-PCR).

FHV7P | Herpesvirus 7 (HHV-7) DNA, Quantitative Real-Time PCR

This test is intended for real-Time PCR.

EGFRS | EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor

This test is intended for identifying non-small cell lung cancers that may respond to epidermal growth factor receptor-targeted therapies.

EGFRW | EGFR Targeted Mutation Analysis with ALK Reflex, Tumor

This test is intended for identifying non-small cell lung cancers that may benefit from treatment with epidermal growth factor receptor -targeted therapies or anaplastic lymphoma kinase inhibitors.

AMGEN | Mycoplasma genitalium, Transcription-Mediated Amplification, Varies

This test is intended for detection of Mycoplasma genitalium in cases of suspected infection.

This test is not intended for use in medico-legal applications.

AMISO | Amylase, Isoenzymes, Serum

This test is intended for ruling out salivary amylase as the cause of elevated serum amylase.

JCHAG | Trypanosoma cruzi Total Antibody, Enzyme-Linked Immunosorbent Assay, Donor, Serum

This test in intended for diagnosis of chronic Trypanosoma cruzi infection (Chagas disease).

CHAGS | Trypanosoma cruzi Total Antibody, Enzyme-Linked Immunosorbent Assay, Serum

This test is intended for diagnosis of chronic Trypanosoma cruzi infection (Chagas disease).

CMPRE | Family Member Comparator Specimen for Exome Sequencing, Varies

This test is intended for submitting a biological family member’s specimen to be used as a comparator for affected patients (probands) undergoing whole exome sequencing.

WESDX | Whole Exome Sequencing for Hereditary Disorders , Varies

This test is intended for serving as a first-tier test to identify a molecular diagnosis in patients with suspected genetic disorders, which can allow for:

  • Better understanding of the natural history/prognosis
  • Targeted management (anticipatory guidance, management changes, specific therapies)
  • Predictive testing of at-risk family members
  • Testing and exclusion of disease in siblings or other relatives
  • Recurrence risk assessment

Serving as a second-tier test for patients in whom previous genetic testing was negative.

Providing a potentially cost-effective alternative to establishing a molecular diagnosis compared to performing multiple independent molecular assays.

RP | Respiratory Panel, PCR, Nasopharyngeal

This test is intended for rapid detection of respiratory infections caused by the following:

  • Adenovirus
  • Coronavirus (serotypes HKU1, NL63, 229E, OC43)
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19)
  • Human metapneumovirus
  • Human rhinovirus/enterovirus
  • Influenza A (H1, H1-2009, H3)
  • Influenza B
  • Parainfluenza virus (serotypes 1-4)
  • Respiratory syncytial virus (RSV)
  • Bordetella pertussis
  • Bordetella parapertussis
  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae

This test is not recommended as a test of cure.

RPB | Respiratory Panel, PCR, Varies

This test is intended for rapid detection of respiratory infections caused by the following:

  • Adenovirus
  • Coronavirus (serotypes HKU1, NL63, 229E, OC43)
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Human metapneumovirus
  • Human rhinovirus/enterovirus
  • Influenza A (H1, H1-2009, H3)
  • Influenza B
  • Parainfluenza virus (serotypes 1-4)
  • Respiratory syncytial virus (RSV)
  • Bordetella pertussis
  • Bordetella parapertussis
  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae

This test is not recommended as a test of cure.

In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:

Chantell Canfield (@chantellcanfield)

Chantell Canfield

Chantell Canfield is a web content coordinator for Mayo Clinic Laboratories. She began working for Mayo Clinic in 2021.